NCT04715646
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 40 versions: 36 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Trial sites reduced: 36 → 32 locations
- Final enrollment: 84 participants (planned 70)
- Study description revised
- Minor Study sites: 34 to 36v38
- Notable Primary and study completion dates: Jul 17, 2029 to Jul 8, 2030v37
- Notable Trial status: Active, Not Recruiting to Recruiting
- Study sites: 30 to 34
- Minor Study sites: 29 to 30v35
Show 30 earlier versionsHide 30 earlier versions
- Minor Study sites: 27 to 29v34
- Minor Study sites revised (27)v33
- Minor Study sites: 26 to 27v32
- Notable Primary and study completion dates: Jul 17, 2025 to Jul 17, 2029v29
- Minor Site details revised at 1 of 26 sitesv27
- Minor Site details revised at 1 of 26 sitesv26
- Minor Study sites: 27 to 26v25
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 79 to confirmed 70
- Study sites: 31 to 27
- Primary and study completion dates: Jul 2, 2025 to Jul 17, 2025
- Minor Study sites: 30 to 31v23
- Minor Primary and study completion dates: May 2, 2025 to Jul 2, 2025v22
Notable Eligibility criteria shortened, about 206 wordsv21 Show 5 more changesShow less
- Enrollment target: 100 to 79
- Primary and study completion dates: May 2025 to May 2, 2025
- Study description shortened, about 25 words
- Site details revised at 4 of 30 sites
- Study title revised
- Minor Site details revised at 1 of 30 sitesv20
- Minor Study sites: 29 to 30v19
- Minor Primary and study completion dates: Apr 2025 to May 2025
- Site details revised at 4 of 29 sites
- Minor Site details revised at 12 of 29 sitesv17
- Minor Study sites: 27 to 29v16
- Minor Study sites: 26 to 27v15
- Minor Study sites: 24 to 26v14
- Minor Study sites: 23 to 24v13
- Minor Study sites: 22 to 23v12
- Minor Study sites: 21 to 22v11
- Minor Study sites: 20 to 21v10
- Minor Study sites: 17 to 20v9
- Minor Study sites: 15 to 17v8
- Minor Study sites: 12 to 15v7
- Minor Study sites: 9 to 12v6
- Minor Study sites: 7 to 9v5
- Minor Study sites: 4 to 7v4
- Minor Study sites: 1 to 4v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 2021 to Mar 11, 2021
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of treatment-emergent adverse events (TEAEs) during the study
Timeframe: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
Incidence of treatment-emergent serious adverse events (SAEs) during the study
Timeframe: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the study
Timeframe: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)
Arms and interventions
BrivaracetamExperimental
LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.
Drugs: Brivaracetam
Sites
32 sites in 7 countries
Japan 19, Hungary 3, Mexico 3, Poland 3, United States 2, Italy 1, Spain 1